{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:22:28Z","timestamp":1776982948759,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.canlet.2007.06.006","type":"journal-article","created":{"date-parts":[[2007,7,24]],"date-time":"2007-07-24T07:10:45Z","timestamp":1185261045000},"page":"186-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["FANCD2 depletion sensitizes cancer cells repopulation ability in vitro"],"prefix":"10.1016","volume":"256","author":[{"given":"Alex","family":"Lyakhovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Surralles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2007.06.006_bib1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1470-2045(06)70757-4","article-title":"Reassessment of the role of induction chemotherapy for head and neck cancer","volume":"7","author":"Gibson","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2007.06.006_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrc1451","article-title":"Radiation oncology: a century of achievements","volume":"9","author":"Bernier","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2007.06.006_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8588(03)00143-6","article-title":"Radiation therapy","author":"Jeremic","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.canlet.2007.06.006_bib4","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1016\/j.lfs.2005.05.024","article-title":"Evaluation of the cytotoxicity, cytostaticity and genotoxicity of argentatins A and B from Parthenium argentatum (Gray)","volume":"77","author":"Parra-Delgado","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2007.06.006_bib5","first-page":"1","article-title":"Endpoints for agents that slow tumor growth","volume":"7","author":"Yu","year":"2006","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.canlet.2007.06.006_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/1568009054863627","article-title":"Tumor necrosis factor: how to make a killer molecule tumor-specific?","volume":"6","author":"Lucas","year":"2005","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2007.06.006_bib7","first-page":"207","article-title":"Molecular targets of ovarian carcinomas with acquired resistance to platinum\/taxane chemotherapy","volume":"3","author":"Kurzeder","year":"2004","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2007.06.006_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1054\/drup.2001.0213","article-title":"If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumour cells","volume":"5","author":"Roninson","year":"2001","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.canlet.2007.06.006_bib9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bjc.6602958","article-title":"Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients","volume":"4","author":"Moureau-Zabotto","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2007.06.006_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.seminoncol.2005.04.028","article-title":"Targeting molecular determinants of tumor chemo-radioresistance","volume":"32","author":"Milas","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2007.06.006_bib11","first-page":"943","article-title":"Mechanisms of therapy-related carcinogenesis","volume":"12","author":"Allan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2007.06.006_bib12","first-page":"323","article-title":"Therapy-associated solid tumors","volume":"4","author":"Travis","year":"2004","journal-title":"Acta Oncol."},{"key":"10.1016\/j.canlet.2007.06.006_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2003.11.015","article-title":"Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB","volume":"44","author":"Griesinger","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2007.06.006_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1634\/theoncologist.11-5-469","article-title":"RADPLAT: an alternative to surgery?","volume":"5","author":"Alkureishi","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2007.06.006_bib15","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1200\/JCO.2002.03.051","article-title":"Treatment of unfavorable childhood Hodgkin\u2019s disease with VEPA and low-dose, involved-field radiation","volume":"20","author":"Friedmann","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2007.06.006_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1056-8719(98)00027-6","article-title":"Therapeutic applications of implantable drug delivery systems","volume":"40","author":"Dash","year":"1998","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.canlet.2007.06.006_bib17","first-page":"1229","article-title":"Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells","volume":"13","author":"Ikuta","year":"2005","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2007.06.006_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/153303460500400405","article-title":"Targeted drug delivery in cancer therapy","volume":"4","author":"Vasir","year":"2005","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2007.06.006_bib19","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1200\/JCO.2005.05.4171","article-title":"DNA repair pathways in clinical practice: lessons from paediatric cancer susceptibility syndromes","volume":"24","author":"Kennedy","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2007.06.006_bib20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ng0905-921","article-title":"Unraveling the Fanconi anemia-DNA repair connection","volume":"37","author":"Thompson","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2007.06.006_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ng1942","article-title":"Fanconi anemia is associated with a defect in the BRCA2 partner PALB2","volume":"39","author":"Xia","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2007.06.006_bib22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ng1947","article-title":"Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer","volume":"39","author":"Reid","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2007.06.006_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2007.03.009","article-title":"Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair","volume":"129","author":"Smogorzewska","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2007.06.006_bib24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1101\/gad.1216304","article-title":"Molecular cross talk among chromosome fragility syndromes","volume":"18","author":"Surrall\u00e9s","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2007.06.006_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1097-2765(01)00173-3","article-title":"Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway","volume":"7","author":"Garcia-Higuera","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2007.06.006_bib26","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1182\/blood-2002-01-0278","article-title":"S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51","volume":"100","author":"Taniguchi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.06.006_bib27","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1101\/gad.1196104","article-title":"ATR couples FANCD2 monoubiquitination to the DNA-damage response","volume":"18","author":"Andreassen","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2007.06.006_bib28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/hmg\/ddh135","article-title":"Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways","volume":"13","author":"Hussain","year":"2004","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.canlet.2007.06.006_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.dnarep.2006.02.007","article-title":"Tetratricopeptide-motif-mediated interaction of FANCG with recombination proteins XRCC3 and BRCA2","volume":"5","author":"Hussain","year":"2006","journal-title":"DNA Repair (Amst.)."},{"key":"10.1016\/j.canlet.2007.06.006_bib30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4161\/cc.3.6.911","article-title":"Fanconi anemia proteins and the s phase checkpoint","volume":"3","author":"Pichierri","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2007.06.006_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/MCB.26.2.425-437.2006","article-title":"Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks","volume":"26","author":"Sobeck","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2007.06.006_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nm852","article-title":"Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors","volume":"5","author":"Taniguchi","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2007.06.006_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc970","article-title":"The Fanconi anaemia\/BRCA pathway","volume":"1","author":"D\u2019Andrea","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2007.06.006_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(03)00111-9","article-title":"FANCF methylation contributes to chemoselectivity in ovarian cancer","volume":"5","author":"Olopade","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2007.06.006_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/cc.2.4.413","article-title":"The Fanconi Anemia\/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers","volume":"2","author":"D\u2019Andrea","year":"2003","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2007.06.006_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2005.07.038","article-title":"Disruption of the Fanconi anemia\/BRCA pathway in sporadic cancer","volume":"232","author":"Lyakhovich","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2007.06.006_bib37","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2004-05-1852","article-title":"Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA\/BRCA pathway","volume":"105","author":"Soulier","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.06.006_bib38","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","article-title":"Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway","volume":"4","author":"Chirnomas","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2007.06.006_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.gt.3302694","article-title":"Prospects of RNA interference therapy for cancer","volume":"6","author":"Pai","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2007.06.006_bib40","first-page":"2115","article-title":"Rad6 overexpression induces multinucleation, centrosome amplification. abnormal mitosis, aneuploidy, and transformation","volume":"62","author":"Shekhar","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2007.06.006_bib41","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.emboj.7601574","article-title":"Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability","volume":"26","author":"Bogliolo","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2007.06.006_bib42","first-page":"61","article-title":"Inhibition of epidermal growth factor receptor by RNA interference in A549 cells","volume":"25","author":"Zhang","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2007.06.006_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.molcel.2005.01.008","article-title":"The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway","volume":"3","author":"Nijman","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2007.06.006_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.cco.0000147383.04709.10","article-title":"DNA methylation and cancer therapy: new developments and expectations","volume":"1","author":"Esteller","year":"2005","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2007.06.006_bib45","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/pmic.200300755","article-title":"Identification of proteins in activated human neutrophils susceptible to tyrosyl radical attack, A proteomic study using a tyrosylating fluorophore","volume":"4","author":"Avram","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.canlet.2007.06.006_bib46","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2007.06.006_bib47","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-05-4282","article-title":"Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer","volume":"66","author":"Rossi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2007.06.006_bib48","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.cgt.7700751","article-title":"Stable and complete overcoming of MDR1\/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference","volume":"11","author":"Stege","year":"2004","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2007.06.006_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/1078-0432.CCR-06-1637","article-title":"Targeting Fanconi anemia\/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models","volume":"13","author":"Gallmeier","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2007.06.006_bib50","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1038\/sj.onc.1205653","article-title":"Killing of leukemic cells with a BCR\/ABL fusion gene by RNA interference (RNAi)","volume":"21","author":"Wilda","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2007.06.006_bib51","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1128\/MCB.01229-06","article-title":"siRNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions","volume":"26","author":"Bartz","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2007.06.006_bib52","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2006.05.018","article-title":"Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1","volume":"4","author":"Navarro","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2007.06.006_bib53","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood-2005-10-4240","article-title":"Molecular pathogenesis of Fanconi anemia: recent progress","volume":"107","author":"Taniguchi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.06.006_bib54","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1158\/0008-5472.CAN-05-3602","article-title":"Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents","volume":"66","author":"Cheung","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2007.06.006_bib55","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1053\/j.gastro.2006.03.016","article-title":"Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options","volume":"130","author":"Gallmeier","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2007.06.006_bib56","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1158\/0008-5472.CAN-04-0245","article-title":"Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer","volume":"64","author":"Narayan","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2007.06.006_bib57","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1365-2141.2003.04640.x","article-title":"Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia","volume":"3","author":"Tischkowitz","year":"2003","journal-title":"J. Haematol."},{"key":"10.1016\/j.canlet.2007.06.006_bib58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.leu.2403280","article-title":"Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia","volume":"18","author":"Tischkowitz","year":"2004","journal-title":"Leukemia"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383507002789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383507002789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:27:29Z","timestamp":1759591649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383507002789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0304383507002789"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2007.06.006","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FANCD2 depletion sensitizes cancer cells repopulation ability in vitro","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2007.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}